de en
  • Paion GmbH
  • Company

    About PAION

    1. History
    2. Management
    3. Supervisory Board

    Contact

    1. Germany
    2. UK

    Career

    1. What does PAIONeering mean to us?
    2. What PAIONeers can expect
    3. Job offers

    Information

    1. Events
    2. Information Request
  • Remimazolam

    Sedation & anesthesia market

    1. Overview
    2. Procedural Sedation (U.S.)
    3. General Anesthesia (Europe)
    4. ICU sedation

    Product Information

    1. About Remimazolam
    2. Clinical trials

    Medical Information

  • Pipeline

    Portfolio

    1. Overview
    2. Remimazolam
    3. GIAPREZA
    4. XERAVA

    Glossary

    1. A_Z
  • Partnering

    Strategy

    1. Partnering strategy
    2. Remimazolam strategy

    Licensing projects

    1. Remimazolam
    2. GIAPREZA
    3. XEVARA
  • Media and Investors

    At a glance

    1. General Information
    2. Contact

    Newsroom

    1. Press Releases
    2. Ad-hoc Releases
    3. Directors' Dealings
    4. Holdings in company

    Information on shares

    1. Chart & Fact sheet
    2. Analysts
    3. Capital actions
    4. Information on CeNeS Acquisition

    Investorcenter

    1. Financial Reports
    2. Presentations
    3. Corporate calendar
    4. Information Request

    Corporate Governance

    1. Declaration on Corporate Governance
    2. Articles of Association
    3. Declaration of Conformity
    4. Code of Conduct
    5. By-Laws Supervisory Board

    Annual general meeting

    2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011 2010
  • Scientific Hub
<p><a href="http://bethecatalyst.net/" target="_blank"><span class="big">Be the catalyst</span><span class="small">Visit our new Scientific Hub here</span></a></p>

Be the catalystVisit our new Scientific Hub here

prev next
  • Media and Investors  » 
  • Newsroom  » 
  • Press Releases  » 
  • 2009
  • 11/04/2009

    PAION AG reports results for the first nine months 2009

    • PDF

  • 11/04/2009

    PAION reports positive results of its short acting anaesthetic/sedative CNS 7056 in a Phase IIa study in upper GI endoscopy

    • PDF

  • 10/28/2009

    Phase Ib study endpoint achieved with PAION's short acting anesthetic/sedative CNS 7056

    • PDF

  • 10/12/2009

    Change in PAION AG Management Board

    • PDF

  • 10/06/2009

    PAION announces completion of Phase Ib study with its short acting anesthetic/sedative CNS 7056

    • PDF

  • 10/05/2009

    Abstract on CNS 7056 has been chosen as one of the best abstracts by the American Society Of Anesthesiologists (ASA)

    • PDF

  • 09/08/2009

    PAION to Present at Five Upcoming Conferences

    • PDF

  • 09/08/2009

    PAION Announces Patient Recruitment for Phase IIa Study with its Short Acting Anesthetic/Sedative CNS 7056 Successfully Completed

    • PDF

  • 08/05/2009

    PAION AG reports results for the first half year 2009

    • PDF

  • 07/15/2009

    Phase Ib und IIa Studien mit Anästhetikum/Sedativum CNS 7056 verlaufen nach Plan

    • PDF

  • 05/13/2009

    PAION AG Reports Results for the First Quarter 2009

    • PDF

  • 05/11/2009

    PAION Completes First Part of Phase Ib Study of the anesthetic/sedative CNS 7056

    • PDF

  • 04/20/2009

    PAION Initiates Phase Ib Study of the Anesthetic/Sedative CNS 7056 in Volunteers Undergoing Colonoscopy

    • PDF

  • 04/15/2009

    PAION Initiates Phase II Trial with its Anesthetic/Sedative CNS 7056

    • PDF

  • 04/09/2009

    PAION and ERGOMED report full data of CNS 5161 Phase IIa study in neuropathic cancer pain

    • PDF

  • 03/17/2009

    PAION AG reports consolidated financial results for the fiscal year 2008

    • PDF

  • 01/08/2009

    Press release: PAION's novel sedative/anaesthetic CNS 7056 meets target profile in human proof of concept study

    • PDF

  • copyright © PAION AG I all rights reserved
  • Imprint
  • Privacy Statement
  • General Terms and Conditions
Paion

Martinstrasse 10-12 | 52062 Aachen | Deutschland

Tel.: +49 241 4453-0 | Fax.: +49 241 4453-100 | e-mail: info@paion.com

Company
  1. About PAION +
    1. History
    2. Management
    3. Supervisory Board
  2. Contact +
    1. Germany
    2. UK
  3. Career +
    1. What does PAIONeering mean to us?
    2. What PAIONeers can expect
    3. Job offers
  4. Information +
    1. Events
    2. Information Request
Remimazolam
  1. Sedation & anesthesia market +
    1. Overview
    2. Procedural Sedation (U.S.)
    3. General Anesthesia (Europe)
    4. ICU sedation
  2. Product Information +
    1. About Remimazolam
    2. Clinical trials
  3. Medical Information
Pipeline
  1. Portfolio +
    1. Overview
    2. Remimazolam
    3. GIAPREZA
    4. XERAVA
  2. Glossary +
    1. A_Z
Partnering
  1. Strategy +
    1. Partnering strategy
    2. Remimazolam strategy
  2. Licensing projects +
    1. Remimazolam
    2. GIAPREZA
    3. XEVARA
Media and Investors
  1. At a glance +
    1. General Information
    2. Contact
  2. Newsroom +
    1. Press Releases
    2. Ad-hoc Releases
    3. Directors' Dealings
    4. Holdings in company
  3. Information on shares +
    1. Chart & Fact sheet
    2. Analysts
    3. Capital actions
    4. Information on CeNeS Acquisition
  4. Investorcenter +
    1. Financial Reports
    2. Presentations
    3. Corporate calendar
    4. Information Request
  5. Corporate Governance +
    1. Declaration on Corporate Governance
    2. Articles of Association
    3. Declaration of Conformity
    4. Code of Conduct
    5. By-Laws Supervisory Board
  6. Annual general meeting +
    1. 2021
    2. 2020
    3. 2019
    4. 2018
    5. 2017
    6. 2016
    7. 2015
    8. 2014
    9. 2013
    10. 2012
    11. 2011
    12. 2010
Scientific Hub
Cookie Settings

This website uses cookies.

Some of them are essential and required for running the website. Others improve your user experience and may be activated or deactivated at your discretion.

Accept all Save
Privacy Statement Imprint